TABLE 1.

HR and MAP in mice chronically infected with T. cruzi in response to treatment with BZ or combination treatment with ASA in the acute phase of infection or left untreated^a

Exptl group	HR (bpm)	MAP (mm Hg)
NI	500 ± 1.4 A	103 ± 0.6 A
NI-BZ	538 ± 3.2 B	103 ± 0.6 A
NI-ASA	505 ± 1.1 A	94 ± 0.5 B
NI-BZ+ASA	504 ± 2.4 A	96 ± 0.2 B,C
I-NT	539 ± 1.4 B	117 ± 0.5 D
I-BZ	602 ± 5.8 D	115 ± 0.4 D
I-ASA	490 ± 2.5 A	103 ± 0.2 A
I-BZ+ASA	537 ± 4.1 B	100 ± 0.9 A,C
I-ASA+Boc-2	544 ± 5.2 B	123 ± 0.8 E
I-BZ+ASA+Boc-2	538 ± 3.1 B	119 ± 0.8 D,E

^aMice were treated daily with 25 mg/kg benznidazole (BZ), aspirin (ASA), or a combination of BZ and ASA by oral gavage at 2 days postinfection for 30 days. The antagonist Boc-2 (10 μM/kg) was intraperitoneally injected from 1 day postinfection every 48 h for 7 days before ASA treatment. Heart rate (HR) and mean arterial pressure (MAP) were measured using CODA (a mouse tail cuff blood pressure system) at 180 days postinfection. Values are means ± standard errors of the means. Values followed by the same letter are not significantly different (P < 0.05; two-way ANOVA with Tukey posttest). NI, uninfected group; I, infected group.